Bio-Techne (TECH) Projected to Post Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is projected to release its Q2 2026 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.43 per share and revenue of $290.2040 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last released its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.42. The company had revenue of $286.56 million during the quarter, compared to the consensus estimate of $292.02 million. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.42 earnings per share. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Trading Up 0.9%

Shares of NASDAQ:TECH opened at $68.23 on Wednesday. The business’s 50 day simple moving average is $62.83 and its 200 day simple moving average is $58.70. Bio-Techne has a 1 year low of $46.01 and a 1 year high of $79.28. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.22 and a quick ratio of 2.81. The company has a market capitalization of $10.63 billion, a P/E ratio of 139.25, a P/E/G ratio of 4.66 and a beta of 1.47.

Bio-Techne Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 28th. Stockholders of record on Monday, November 17th were issued a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Monday, November 17th. Bio-Techne’s dividend payout ratio is 65.31%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sherbrooke Park Advisers LLC bought a new stake in shares of Bio-Techne in the 3rd quarter valued at $245,000. Focus Partners Wealth acquired a new position in Bio-Techne in the third quarter valued at $340,000. Lazard Asset Management LLC boosted its position in Bio-Techne by 8.8% during the third quarter. Lazard Asset Management LLC now owns 6,957 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 562 shares during the last quarter. Certuity LLC acquired a new stake in Bio-Techne during the 3rd quarter worth about $335,000. Finally, E Fund Management Co. Ltd. raised its position in shares of Bio-Techne by 4.5% in the 2nd quarter. E Fund Management Co. Ltd. now owns 5,497 shares of the biotechnology company’s stock worth $283,000 after acquiring an additional 235 shares in the last quarter. 98.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group boosted their price target on Bio-Techne from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. TD Cowen restated a “buy” rating on shares of Bio-Techne in a research report on Tuesday, October 14th. Argus increased their price target on shares of Bio-Techne from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, November 20th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. Finally, Evercore ISI set a $62.00 target price on Bio-Techne and gave the stock an “in-line” rating in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $70.57.

Bio-Techne Company Profile

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.